Table 3 Overview of assumed clinical parameters for DVT and/or PE patients
Probability, mean (SE) | DVT patients | PE patients | Source |
|---|---|---|---|
Event/outcome | Â | Â | Â |
Incidence of recurrent VTE (HR) | 0.68 (0.218) | 1.123 (0.207) | * |
Incidence of major bleeding (HR) | 0.646 (0.242) | 0.493 (0.24) | * |
Incidence of NMCR bleeding (RR) | 1.055 (0.123) | 1.001 (0.088) | * |
Probability that a recurrent VTE is a DVT | 0.483 (0.054) | 0.372 (0.050) | * |
Probability that a major bleeding event is a (major) IC bleed | 0.125 (0.058) | 0.143 (0.076) | * |
Discontinuation | Â | Â | Â |
Patients with IC bleeding events | 1.00 (0.0) | 1.00 (0.0) | * |
Patients with major EC bleeding events | 0.400 (0.089) | 0.164 (0.045) | * |
Patients with NMCR bleeding events | 0.110 (0.020) | 0.054 (0.010) | * |
For any other reason (additional) 3–12 months | 0.019 (0.001) | 0.021 (0.001) | * |
For any other reason (additional) >12Â months | 0.036 (0.013) | 0.036 (0.013) | Boggon 2011 [62] |
| Â | DVT and PE patients | Â | |
Risks of subsequent morbidities | |||
Recurrent VTE (per 3-month time step) | 0.013 (0.074) | Prandoni 2007 [41] | |
Progression to CTEPH after a PE | 0.013 (0.002) | Miniati 2006 [38] | |
Cumulative incidence of severe PTS (to 1Â year) | 0.027 (0.007) | Prandoni 1997 [40] | |
Cumulative incidence of severe PTS (to 5Â years) | 0.081 (0.012) | Prandoni 1997 [40] | |
Mortality associated with another model event | |||
PE (during acute treatment phase) | 0.250 (0.041) | * | |
PE (after acute treatment phase) | 0.331 (0.041) | Prandoni 1997 [40] | |
Major IC bleeding | 0.436 (0.036) | Linkins 2010 [42] | |
Major EC bleeding | 0.039 (0.007) | * | |
CTEPH (per 3-month cycle) | 0.025 (0.020) | Condliffe 2008 [43] | |